In hepatocellular carcinoma (HCC), SIRT7 directly deacetylates the transcription factor myocyte enhancer factor 2D (MEF2D), thereby reducing its transcriptional activity and suppressing PD-L1 expression. Here, MEF2D is linked to hepatocellular carcinoma.